Home
About
Overview
Sharing Data
ORCID
Help
History (73)
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study.
Basic residues in azurocidin/HBP contribute to both heparin binding and antimicrobial activity.
Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.
Will a 5-ASA a day keep the cancer (and dysplasia) away?
See All 73 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Will a 5-ASA a day keep the cancer (and dysplasia) away?
Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005 Jun; 100(6):1354-6.
View in:
PubMed
subject areas
Anti-Inflammatory Agents, Non-Steroidal
Colitis, Ulcerative
Colorectal Neoplasms
Disease Progression
Humans
Mesalamine
Risk Factors
Treatment Outcome
authors with profiles
David Rubin